ADBiotech Co

ADBiotech Co Tangible Book Value per Share

The Tangible Book Value per Share of ADBiotech Co (179530.KQ) as of Oct 15, 2026 is 1,676.41 KRW. In the previous year, Tangible Book Value per Share was 353.84 KRW — a change of 373.78% (higher).

Tangible Book Value per Share

1,676.41KRW

YoY

373.78%

Last updated:

Tangible Book Value per Share of ADBiotech Co is 2025 1,676.41 KRW. Tangible Book Value per Share of ADBiotech Co was 2024 353.84 KRW. It decreases by 373.78% higher compared to the previous year.

The ADBiotech Co Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
492.01 KRW
Jan 1, 2019
762.31 KRW
Jan 1, 2020
1,019.16 KRW
Jan 1, 2021
558.02 KRW
Jan 1, 2022
1,770.48 KRW
Jan 1, 2023
1,229.37 KRW
Jan 1, 2024
353.84 KRW
Jan 1, 2025
1,676.41 KRW
The ADBiotech Co Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
1,676.41KRW+373.78%
353.84KRW-71.22%
1,229.37KRW-30.56%
1,770.48KRW+217.28%
558.02KRW-45.25%
1,019.16KRW+33.69%
762.31KRW+54.94%
492.01KRW+58.16%
311.08KRW+231.55%
93.83KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ADBiotech Co Stock analysis

What does ADBiotech Co do? ADbiotech Co., Ltd. is a South Korean enterprise operating within the health care sector, specifically categorized under the pharmaceuticals industry. The company is headquartered in Chuncheon, located in the Gangwon-Do province, and maintains a digital presence at http://www.adbiotech.com/. ADBiotech went public on December 24, 2019, marking its entry into the stock market with the ticker symbol 179530.KQ and the International Securities Identification Number KR7179530001. The firm is primarily engaged in the research and development of chemical products designed for use in pharmaceuticals, stockbreeding, and fisheries. Its business operations are structured around two distinct segments: Veterinary Medicine and Supplementary Feed. The Veterinary Medicine segment focuses on the manufacture and sale of a diverse range of animal health products. This includes antibiotics, which are critical for treating bacterial infections in livestock and pets. The company also produces anticoccidial agents, which are used to prevent and treat coccidiosis, a common parasitic disease in animals. Additionally, the segment covers antimicrobial agents and nervous system agents, addressing various neurological and microbial health issues in veterinary patients. Synthetic antibacterial agents are also part of this portfolio, providing effective solutions for bacterial control in animal health management. The Supplementary Feed segment complements the veterinary offerings by engaging in the manufacture and sale of functional supplementary feeds. These products are designed to enhance the nutritional value of animal diets, supporting overall health and productivity in stockbreeding operations. By offering functional supplementary feeds and other related products, ADBiotech aims to provide comprehensive solutions that address both medical and nutritional needs in the agricultural and veterinary sectors. The company's dual-segment approach allows it to cater to a broad spectrum of customers, from veterinary clinics and animal hospitals to large-scale agricultural operations. Through its focus on research and development, ADBiotech seeks to innovate and improve the quality of its chemical products, ensuring they meet the evolving demands of the pharmaceutical and agricultural industries. As a publicly traded company, ADBiotech is subject to regulatory oversight and reporting requirements, which help maintain transparency and accountability for its investors and stakeholders. The company's presence in Chuncheon, a region known for its agricultural and industrial activities, positions it well to serve the local and national markets while potentially expanding its reach internationally. Overall, ADBiotech Co., Ltd. plays a significant role in the South Korean health care and pharmaceutical landscape, contributing to the advancement of veterinary medicine and animal nutrition through its specialized product offerings and commitment to research and development. ADBiotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ADBiotech Co stock

Tangible Book Value per Share of ADBiotech Co is 1,676.41 KRW in 2025.

Tangible Book Value per Share of ADBiotech Co changed from 353.84 KRW to 1,676.41 KRW, representing a 373.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share ADBiotech Co since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ADBiotech Co

All Key Metrics — ADBiotech Co